Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma | 89 | 2023 | 1786 | 9.520 |
Why?
|
Chordoma | 27 | 2023 | 346 | 5.570 |
Why?
|
Soft Tissue Neoplasms | 30 | 2023 | 1151 | 3.850 |
Why?
|
Spinal Neoplasms | 23 | 2022 | 716 | 3.810 |
Why?
|
Retroperitoneal Neoplasms | 20 | 2021 | 329 | 3.620 |
Why?
|
Extremities | 25 | 2018 | 864 | 2.680 |
Why?
|
Sacrum | 13 | 2023 | 281 | 2.220 |
Why?
|
Radiotherapy Dosage | 52 | 2021 | 2895 | 2.060 |
Why?
|
Photons | 17 | 2019 | 580 | 2.000 |
Why?
|
Bone Neoplasms | 22 | 2021 | 2532 | 1.830 |
Why?
|
Radiation Oncology | 13 | 2021 | 560 | 1.790 |
Why?
|
Radiotherapy, Conformal | 15 | 2020 | 549 | 1.690 |
Why?
|
Radiotherapy | 13 | 2021 | 1503 | 1.450 |
Why?
|
Osteosarcoma | 11 | 2019 | 898 | 1.280 |
Why?
|
Tumor Burden | 15 | 2017 | 1886 | 1.150 |
Why?
|
Radiotherapy, Adjuvant | 28 | 2021 | 1788 | 1.130 |
Why?
|
Neoplasm Recurrence, Local | 39 | 2021 | 9269 | 1.060 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 19 | 2021 | 1659 | 1.050 |
Why?
|
Chondrosarcoma | 8 | 2019 | 296 | 1.020 |
Why?
|
Fibromatosis, Aggressive | 6 | 2019 | 125 | 0.960 |
Why?
|
Neoadjuvant Therapy | 20 | 2021 | 2809 | 0.870 |
Why?
|
Radiotherapy, Intensity-Modulated | 11 | 2020 | 801 | 0.850 |
Why?
|
Cauda Equina | 1 | 2021 | 45 | 0.770 |
Why?
|
Radiotherapy, High-Energy | 4 | 2018 | 228 | 0.700 |
Why?
|
Abdominal Neoplasms | 3 | 2017 | 286 | 0.660 |
Why?
|
Neoplasms, Second Primary | 6 | 2020 | 1058 | 0.650 |
Why?
|
Spinal Cord Neoplasms | 3 | 2017 | 264 | 0.610 |
Why?
|
Organs at Risk | 7 | 2020 | 358 | 0.600 |
Why?
|
Brachytherapy | 9 | 2021 | 1239 | 0.590 |
Why?
|
Chondrosarcoma, Mesenchymal | 1 | 2016 | 12 | 0.570 |
Why?
|
Combined Modality Therapy | 44 | 2021 | 8549 | 0.530 |
Why?
|
Negative-Pressure Wound Therapy | 3 | 2022 | 155 | 0.510 |
Why?
|
Humans | 225 | 2023 | 759255 | 0.500 |
Why?
|
Thoracic Vertebrae | 3 | 2015 | 597 | 0.490 |
Why?
|
Misonidazole | 1 | 2014 | 33 | 0.490 |
Why?
|
Lumbar Vertebrae | 5 | 2023 | 1851 | 0.480 |
Why?
|
Radiation Injuries | 14 | 2016 | 1183 | 0.480 |
Why?
|
Aged | 96 | 2021 | 168617 | 0.470 |
Why?
|
Preoperative Care | 9 | 2021 | 2256 | 0.460 |
Why?
|
Spine | 3 | 2017 | 1110 | 0.450 |
Why?
|
Middle Aged | 111 | 2021 | 219653 | 0.450 |
Why?
|
Skull Base Neoplasms | 2 | 2016 | 269 | 0.450 |
Why?
|
Aged, 80 and over | 46 | 2021 | 58867 | 0.440 |
Why?
|
Adult | 103 | 2021 | 219390 | 0.430 |
Why?
|
Disease-Free Survival | 16 | 2018 | 6813 | 0.430 |
Why?
|
Thoracic Neoplasms | 1 | 2014 | 266 | 0.410 |
Why?
|
Histiocytoma, Malignant Fibrous | 3 | 2014 | 55 | 0.410 |
Why?
|
Cell Hypoxia | 1 | 2014 | 657 | 0.400 |
Why?
|
Photochemotherapy | 11 | 1997 | 808 | 0.400 |
Why?
|
Neoplasms | 15 | 2020 | 22019 | 0.400 |
Why?
|
Treatment Outcome | 50 | 2022 | 64879 | 0.390 |
Why?
|
Patient Positioning | 2 | 2013 | 327 | 0.390 |
Why?
|
Scattering, Radiation | 3 | 2017 | 488 | 0.380 |
Why?
|
Medication Reconciliation | 1 | 2013 | 151 | 0.370 |
Why?
|
Liposarcoma | 4 | 2016 | 283 | 0.360 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 17 | 2019 | 11653 | 0.360 |
Why?
|
Retrospective Studies | 50 | 2022 | 80121 | 0.350 |
Why?
|
Radiation-Sensitizing Agents | 3 | 1998 | 345 | 0.350 |
Why?
|
Chemotherapy, Adjuvant | 15 | 2017 | 3519 | 0.350 |
Why?
|
Head and Neck Neoplasms | 7 | 2014 | 2876 | 0.340 |
Why?
|
Follow-Up Studies | 31 | 2019 | 39216 | 0.340 |
Why?
|
Spinal Cord | 2 | 2016 | 1815 | 0.340 |
Why?
|
Male | 124 | 2021 | 358719 | 0.340 |
Why?
|
Adolescent | 45 | 2021 | 87560 | 0.330 |
Why?
|
Female | 127 | 2021 | 390240 | 0.330 |
Why?
|
Young Adult | 33 | 2021 | 58483 | 0.330 |
Why?
|
Survival Rate | 26 | 2019 | 12800 | 0.330 |
Why?
|
Relative Biological Effectiveness | 8 | 2017 | 312 | 0.330 |
Why?
|
Medical History Taking | 1 | 2013 | 773 | 0.320 |
Why?
|
Dose-Response Relationship, Radiation | 9 | 2019 | 879 | 0.310 |
Why?
|
Tomography, X-Ray Computed | 17 | 2023 | 20461 | 0.300 |
Why?
|
Cyclotrons | 1 | 2007 | 30 | 0.300 |
Why?
|
Radiodermatitis | 3 | 2019 | 58 | 0.300 |
Why?
|
Neoplasms, Radiation-Induced | 5 | 2019 | 549 | 0.290 |
Why?
|
Hematoporphyrin Photoradiation | 5 | 1994 | 17 | 0.290 |
Why?
|
Medical Records | 1 | 2013 | 1406 | 0.290 |
Why?
|
Protons | 4 | 2022 | 1113 | 0.280 |
Why?
|
Neoplasm, Residual | 5 | 2014 | 1007 | 0.270 |
Why?
|
Practice Guidelines as Topic | 7 | 2017 | 7460 | 0.270 |
Why?
|
Kaplan-Meier Estimate | 12 | 2019 | 6532 | 0.270 |
Why?
|
Consensus | 8 | 2021 | 3095 | 0.270 |
Why?
|
Cholangiocarcinoma | 3 | 2018 | 546 | 0.270 |
Why?
|
Isotretinoin | 2 | 1998 | 131 | 0.260 |
Why?
|
Paranasal Sinus Neoplasms | 2 | 2016 | 240 | 0.260 |
Why?
|
Postoperative Care | 5 | 2021 | 1478 | 0.260 |
Why?
|
Fractures, Spontaneous | 2 | 2019 | 231 | 0.260 |
Why?
|
Fibrosarcoma | 2 | 2021 | 308 | 0.250 |
Why?
|
Radiosurgery | 3 | 2020 | 1341 | 0.250 |
Why?
|
Retreatment | 2 | 2021 | 600 | 0.250 |
Why?
|
Dihematoporphyrin Ether | 4 | 1994 | 33 | 0.250 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 2630 | 0.240 |
Why?
|
Nerve Sheath Neoplasms | 2 | 2019 | 167 | 0.240 |
Why?
|
Physicians | 1 | 2023 | 4586 | 0.240 |
Why?
|
Anus Neoplasms | 2 | 2019 | 329 | 0.240 |
Why?
|
Neoplasm Staging | 17 | 2021 | 11123 | 0.230 |
Why?
|
Liver Neoplasms | 5 | 2019 | 4312 | 0.230 |
Why?
|
Limb Salvage | 3 | 2016 | 467 | 0.230 |
Why?
|
Carcinoma, Hepatocellular | 4 | 2019 | 2295 | 0.230 |
Why?
|
Fluorouracil | 5 | 2019 | 1620 | 0.230 |
Why?
|
Iridium Radioisotopes | 1 | 2003 | 26 | 0.230 |
Why?
|
Enteritis | 1 | 2005 | 162 | 0.230 |
Why?
|
Osteotomy | 1 | 2009 | 834 | 0.220 |
Why?
|
Feasibility Studies | 11 | 2019 | 5194 | 0.220 |
Why?
|
Pancreatic Neoplasms | 7 | 2019 | 5310 | 0.220 |
Why?
|
Bandages | 2 | 2021 | 269 | 0.210 |
Why?
|
Interferon-alpha | 2 | 1998 | 918 | 0.210 |
Why?
|
Particle Accelerators | 2 | 2018 | 174 | 0.210 |
Why?
|
Hemangiosarcoma | 2 | 2020 | 218 | 0.210 |
Why?
|
Prognosis | 23 | 2021 | 29561 | 0.210 |
Why?
|
Yttrium Radioisotopes | 1 | 2003 | 107 | 0.210 |
Why?
|
Doxorubicin | 7 | 2012 | 2203 | 0.200 |
Why?
|
Mesna | 4 | 2012 | 62 | 0.200 |
Why?
|
Survival Analysis | 13 | 2019 | 10185 | 0.200 |
Why?
|
Ifosfamide | 5 | 2012 | 232 | 0.200 |
Why?
|
Biopsy, Needle | 2 | 2006 | 1633 | 0.200 |
Why?
|
Angiogenesis Inhibitors | 2 | 2015 | 2048 | 0.190 |
Why?
|
Intraoperative Period | 4 | 2010 | 516 | 0.190 |
Why?
|
Dura Mater | 1 | 2003 | 290 | 0.190 |
Why?
|
Positron-Emission Tomography | 3 | 2020 | 6436 | 0.190 |
Why?
|
Abdominal Wall | 2 | 2014 | 166 | 0.190 |
Why?
|
Neurofibromatosis 1 | 2 | 2019 | 561 | 0.190 |
Why?
|
Boronic Acids | 1 | 2005 | 914 | 0.190 |
Why?
|
Eye Diseases | 1 | 2006 | 651 | 0.190 |
Why?
|
Proteome | 1 | 2010 | 1849 | 0.180 |
Why?
|
Child | 27 | 2019 | 79623 | 0.180 |
Why?
|
Imaging, Three-Dimensional | 1 | 2013 | 4040 | 0.170 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2019 | 4025 | 0.170 |
Why?
|
Magnetic Resonance Imaging | 14 | 2017 | 36160 | 0.170 |
Why?
|
Treatment Failure | 6 | 2017 | 2642 | 0.170 |
Why?
|
Thoracic Wall | 2 | 2013 | 199 | 0.170 |
Why?
|
Nephrectomy | 2 | 2015 | 1017 | 0.170 |
Why?
|
Pyrazines | 1 | 2005 | 1201 | 0.160 |
Why?
|
Bile Duct Neoplasms | 2 | 2015 | 601 | 0.160 |
Why?
|
Arm | 2 | 2013 | 583 | 0.160 |
Why?
|
Disease Management | 2 | 2021 | 2498 | 0.160 |
Why?
|
Dacarbazine | 4 | 2012 | 560 | 0.160 |
Why?
|
Breast Neoplasms | 11 | 2020 | 21022 | 0.160 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 3613 | 0.160 |
Why?
|
Abdominal Fat | 1 | 2020 | 223 | 0.160 |
Why?
|
Gastrointestinal Stromal Tumors | 2 | 2014 | 614 | 0.150 |
Why?
|
Leukemia, Radiation-Induced | 1 | 2017 | 39 | 0.150 |
Why?
|
Deoxycytidine | 2 | 2014 | 860 | 0.150 |
Why?
|
Child, Preschool | 16 | 2019 | 41935 | 0.150 |
Why?
|
Radiometry | 4 | 2013 | 813 | 0.150 |
Why?
|
Losartan | 1 | 2019 | 258 | 0.150 |
Why?
|
Radiography | 7 | 2015 | 6964 | 0.150 |
Why?
|
Medulloblastoma | 2 | 2017 | 677 | 0.150 |
Why?
|
Solitary Fibrous Tumors | 1 | 2018 | 67 | 0.140 |
Why?
|
Peritoneal Neoplasms | 3 | 1993 | 706 | 0.140 |
Why?
|
Prospective Studies | 18 | 2019 | 54204 | 0.140 |
Why?
|
Neuroectodermal Tumors, Primitive | 2 | 1995 | 136 | 0.140 |
Why?
|
Central Nervous System Neoplasms | 1 | 2005 | 908 | 0.140 |
Why?
|
Proteomics | 1 | 2010 | 3804 | 0.140 |
Why?
|
Liver Failure | 1 | 2019 | 249 | 0.140 |
Why?
|
Time Factors | 16 | 2019 | 40109 | 0.140 |
Why?
|
Radiation Tolerance | 4 | 2015 | 480 | 0.130 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2016 | 43 | 0.130 |
Why?
|
Postoperative Complications | 8 | 2018 | 15672 | 0.130 |
Why?
|
Cell Dedifferentiation | 1 | 2016 | 121 | 0.130 |
Why?
|
Ireland | 2 | 2013 | 171 | 0.120 |
Why?
|
Pleural Neoplasms | 4 | 1994 | 609 | 0.120 |
Why?
|
Intestine, Small | 4 | 2017 | 1206 | 0.120 |
Why?
|
Th2 Cells | 4 | 2001 | 1048 | 0.120 |
Why?
|
Sacrococcygeal Region | 1 | 2014 | 53 | 0.120 |
Why?
|
Algorithms | 8 | 2023 | 13946 | 0.120 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 3 | 2001 | 900 | 0.120 |
Why?
|
Radiation, Ionizing | 1 | 2015 | 251 | 0.120 |
Why?
|
Liposarcoma, Myxoid | 2 | 2014 | 60 | 0.110 |
Why?
|
Pyrimidines | 3 | 2018 | 2996 | 0.110 |
Why?
|
Nose Neoplasms | 1 | 2016 | 249 | 0.110 |
Why?
|
Linear Energy Transfer | 3 | 2017 | 152 | 0.110 |
Why?
|
Pain, Intractable | 1 | 1994 | 132 | 0.110 |
Why?
|
Pelvic Neoplasms | 1 | 2015 | 248 | 0.110 |
Why?
|
Skin Neoplasms | 4 | 2007 | 5796 | 0.110 |
Why?
|
Perfusion Imaging | 1 | 2015 | 196 | 0.110 |
Why?
|
Databases, Factual | 4 | 2017 | 8000 | 0.110 |
Why?
|
Fibromatosis, Abdominal | 1 | 2012 | 21 | 0.110 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2013 | 53 | 0.110 |
Why?
|
Myxosarcoma | 1 | 2012 | 11 | 0.110 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2017 | 586 | 0.110 |
Why?
|
Analysis of Variance | 3 | 2009 | 6242 | 0.110 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 367 | 0.100 |
Why?
|
Proportional Hazards Models | 9 | 2019 | 12522 | 0.100 |
Why?
|
Mastocytosis | 1 | 1994 | 149 | 0.100 |
Why?
|
Observer Variation | 3 | 2015 | 2596 | 0.100 |
Why?
|
Sarcoma, Synovial | 2 | 2014 | 151 | 0.100 |
Why?
|
Preoperative Period | 2 | 2012 | 555 | 0.100 |
Why?
|
Cerebellar Neoplasms | 1 | 2017 | 585 | 0.100 |
Why?
|
Hepatectomy | 1 | 2015 | 562 | 0.100 |
Why?
|
Endpoint Determination | 1 | 2014 | 597 | 0.100 |
Why?
|
Antineoplastic Agents | 8 | 2015 | 13621 | 0.090 |
Why?
|
Professional Staff Committees | 2 | 2001 | 38 | 0.090 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 620 | 0.090 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2014 | 1708 | 0.090 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2012 | 674 | 0.090 |
Why?
|
Lung Neoplasms | 6 | 2020 | 13238 | 0.090 |
Why?
|
Bone Diseases | 1 | 1994 | 418 | 0.090 |
Why?
|
Asymptomatic Diseases | 1 | 2013 | 573 | 0.090 |
Why?
|
Bone Density | 1 | 2023 | 3518 | 0.090 |
Why?
|
Medical Illustration | 1 | 2011 | 135 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2016 | 1114 | 0.090 |
Why?
|
Pilot Projects | 4 | 2023 | 8540 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 640 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2014 | 729 | 0.090 |
Why?
|
Foot | 1 | 1994 | 573 | 0.090 |
Why?
|
Terminology as Topic | 2 | 2014 | 1534 | 0.090 |
Why?
|
Radiation Dosage | 5 | 2017 | 1955 | 0.080 |
Why?
|
Thigh | 1 | 2011 | 239 | 0.080 |
Why?
|
Esophageal Neoplasms | 1 | 2020 | 1655 | 0.080 |
Why?
|
Perioperative Care | 1 | 2017 | 1030 | 0.080 |
Why?
|
Intraoperative Care | 5 | 2017 | 768 | 0.080 |
Why?
|
Biopsy | 1 | 2021 | 6772 | 0.080 |
Why?
|
Cell Proliferation | 3 | 2016 | 10440 | 0.080 |
Why?
|
Immunoconjugates | 3 | 2001 | 947 | 0.080 |
Why?
|
Hand | 1 | 1994 | 903 | 0.080 |
Why?
|
Photosensitizing Agents | 1 | 1993 | 608 | 0.080 |
Why?
|
Spinal Fractures | 1 | 2015 | 698 | 0.080 |
Why?
|
Edema | 1 | 2013 | 772 | 0.080 |
Why?
|
Adenocarcinoma | 4 | 2018 | 6311 | 0.080 |
Why?
|
Th1 Cells | 4 | 2001 | 1033 | 0.080 |
Why?
|
Sarcoma, Clear Cell | 1 | 2009 | 72 | 0.080 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1524 | 0.080 |
Why?
|
Perception | 1 | 2015 | 1189 | 0.080 |
Why?
|
Quality of Life | 5 | 2021 | 13284 | 0.080 |
Why?
|
Lower Extremity | 2 | 2013 | 1194 | 0.080 |
Why?
|
Brain Neoplasms | 6 | 2014 | 8953 | 0.080 |
Why?
|
Mastectomy | 2 | 2013 | 1834 | 0.080 |
Why?
|
Myelodysplastic Syndromes | 1 | 2018 | 1395 | 0.080 |
Why?
|
Drug Information Services | 1 | 2008 | 51 | 0.080 |
Why?
|
beta Catenin | 1 | 2013 | 1043 | 0.080 |
Why?
|
Furans | 1 | 2009 | 198 | 0.080 |
Why?
|
Massachusetts | 3 | 2010 | 8788 | 0.070 |
Why?
|
Wound Healing | 2 | 2012 | 2782 | 0.070 |
Why?
|
Mitomycin | 2 | 2019 | 262 | 0.070 |
Why?
|
Neurosurgical Procedures | 1 | 2018 | 2052 | 0.070 |
Why?
|
Chondromatosis, Synovial | 1 | 2007 | 17 | 0.070 |
Why?
|
Lymphangiosarcoma | 1 | 2006 | 14 | 0.070 |
Why?
|
Multiple Myeloma | 1 | 2005 | 5131 | 0.070 |
Why?
|
Imidazoles | 2 | 2004 | 1175 | 0.070 |
Why?
|
Gastrointestinal Diseases | 1 | 2015 | 1190 | 0.070 |
Why?
|
Alkyl and Aryl Transferases | 2 | 2004 | 86 | 0.070 |
Why?
|
Respiration | 1 | 2013 | 1648 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3526 | 0.070 |
Why?
|
Osteolysis, Essential | 1 | 2006 | 30 | 0.070 |
Why?
|
Lung | 6 | 2006 | 9982 | 0.070 |
Why?
|
Facility Design and Construction | 1 | 2007 | 85 | 0.070 |
Why?
|
Muscle Neoplasms | 1 | 2008 | 133 | 0.070 |
Why?
|
Regression Analysis | 1 | 2016 | 6359 | 0.070 |
Why?
|
Research Design | 3 | 2014 | 6168 | 0.070 |
Why?
|
Radiation-Protective Agents | 3 | 1992 | 88 | 0.070 |
Why?
|
Carbon | 1 | 2010 | 671 | 0.070 |
Why?
|
Microvessels | 1 | 2010 | 572 | 0.070 |
Why?
|
Vascular Neoplasms | 1 | 2008 | 167 | 0.070 |
Why?
|
Tumor Cells, Cultured | 5 | 2009 | 6131 | 0.070 |
Why?
|
Leiomyosarcoma | 1 | 2010 | 424 | 0.060 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2006 | 800 | 0.060 |
Why?
|
Lymphatic Metastasis | 2 | 2013 | 2943 | 0.060 |
Why?
|
|